BR0317340A - Hfc formulations in tiotropium containing solution - Google Patents

Hfc formulations in tiotropium containing solution

Info

Publication number
BR0317340A
BR0317340A BR0317340-2A BR0317340A BR0317340A BR 0317340 A BR0317340 A BR 0317340A BR 0317340 A BR0317340 A BR 0317340A BR 0317340 A BR0317340 A BR 0317340A
Authority
BR
Brazil
Prior art keywords
solution
tiotropium
formulations
hfc
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
BR0317340-2A
Other languages
Portuguese (pt)
Inventor
Sabine Six
Christel Schmelzer
Friedrich Schmidt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH Co KG filed Critical Boehringer Ingelheim Pharma GmbH Co KG
Publication of BR0317340A publication Critical patent/BR0317340A/en
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

"FORMULAçõES DE HFC EM SOLUçãO CONTENDO TIOTRóPIO". A presente invenção refere-se a formulações farmacêuticas em solução estáveis que contêm tiotrópio adequadas para administração por aerossol. Mais particularmente, esta invenção refere-se a formulações farmacêuticas em solução estáveis que contêm tiotrópio adequadas para administração por aerossol em que um ácido inorgânico ou um ácido orgânico é adicionado à formulação em solução por aerossol que contém um sal de tiotrópio, de preferência o brometo de tiotrópio em solução com um hidrofluorocarboneto (HFC) ambientalmente inofensivo como um propulsor, juntamente com um composto orgânico como um co-solvente. O ácido fornece estabilidade contra a degradação ou a decomposição do medicamento resultante amplamente da interação do medicamento com o co-solvente e/ou com a água presente na formulação em solução."HFC FORMULATIONS IN SOLUTION CONTAINING THIOTROPE". The present invention relates to stable solution pharmaceutical formulations containing tiotropium suitable for aerosol administration. More particularly, this invention relates to stable tiotropium-containing pharmaceutical solution formulations suitable for aerosol administration wherein an inorganic acid or an organic acid is added to the aerosol solution-formulation containing a tiotropium salt, preferably bromide. of tiotropium in solution with an environmentally harmless hydrofluorocarbon (HFC) as a propellant, together with an organic compound as a co-solvent. The acid provides stability against drug degradation or decomposition largely resulting from drug interaction with the co-solvent and / or water present in the solution formulation.

BR0317340-2A 2002-12-16 2003-12-04 Hfc formulations in tiotropium containing solution Expired - Fee Related BR0317340A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02028238 2002-12-16
PCT/EP2003/013692 WO2004054580A1 (en) 2002-12-16 2003-12-04 Tiotropium containing hfc solution formulations

Publications (1)

Publication Number Publication Date
BR0317340A true BR0317340A (en) 2005-11-08

Family

ID=32524008

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0317340-2A Expired - Fee Related BR0317340A (en) 2002-12-16 2003-12-04 Hfc formulations in tiotropium containing solution

Country Status (13)

Country Link
EP (1) EP1575588A1 (en)
JP (1) JP2006510680A (en)
KR (1) KR20050085650A (en)
CN (1) CN1726038A (en)
AU (1) AU2003303029A1 (en)
BR (1) BR0317340A (en)
CA (1) CA2510043A1 (en)
IL (1) IL169178A0 (en)
MX (1) MXPA05006383A (en)
PL (1) PL375868A1 (en)
RU (1) RU2005122444A (en)
WO (1) WO2004054580A1 (en)
ZA (1) ZA200503546B (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7273603B2 (en) * 2003-07-11 2007-09-25 Boehringer Ingelheim International Gmbh HFC solution formulations containing an anticholinergic
CA2606549A1 (en) * 2005-05-02 2006-11-09 Boehringer Ingelheim International Gmbh Crystalline forms of tiotropium bromide
RU2007144531A (en) * 2005-05-02 2009-06-10 БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) NEW CRYSTAL FORMS OF THIOTROPYBROMIDE
JP5086267B2 (en) 2005-12-19 2012-11-28 シコール インコーポレイティド Novel form of tiotropium bromide and process for producing it
US9108962B2 (en) 2005-12-19 2015-08-18 Sicor, Inc. Forms of tiotropium bromide and processes for preparation thereof
EP2201934A1 (en) 2008-12-23 2010-06-30 CHIESI FARMACEUTICI S.p.A. Tiotropium aerosol formulation products with improved chemical stability
GEP20166479B (en) 2009-12-23 2016-05-25 Chiesi Farma Spa Aerosol formulation for copd
CN102665679B (en) 2009-12-23 2014-11-26 奇斯药制品公司 Combination therapy for COPD
GB201200525D0 (en) * 2011-12-19 2012-02-29 Teva Branded Pharmaceutical Prod R & D Inc An inhalable medicament
GB201200504D0 (en) 2011-12-19 2012-02-22 Teva Branded Pharmaceutical Prod R & D Inc An inhaler
JP6335798B2 (en) 2012-02-28 2018-05-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング New propellant-containing tiotropium formulation
US20150250713A1 (en) * 2012-10-23 2015-09-10 Cipla Limited Pharmaceutical Composition
DK2897588T3 (en) * 2013-11-22 2019-08-12 Teva Branded Pharmaceutical Products R&D Inc INHALABLE MEDICINAL PRODUCT
US10034866B2 (en) 2014-06-19 2018-07-31 Teva Branded Pharmaceutical Products R&D, Inc. Inhalable medicament comprising tiotropium
MY202069A (en) 2016-09-19 2024-03-31 Mexichem Fluor Sa De Cv Pharmaceutical composition
CN115252552A (en) * 2016-09-19 2022-11-01 墨西哥氟石股份公司 Pharmaceutical composition
US11260052B2 (en) 2016-09-19 2022-03-01 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
CN113069417A (en) * 2016-09-19 2021-07-06 墨西哥氟石股份公司 Pharmaceutical composition
EP3515425B1 (en) 2016-09-19 2021-06-09 Mexichem Fluor S.A. de C.V. Pharmaceutical composition comprising salmeterol

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ284203B6 (en) * 1992-12-09 1998-09-16 Boehringer Ingelheim Pharmaceuticals Inc. Pharmaceutical preparation
DE10056104A1 (en) * 2000-11-13 2002-05-23 Boehringer Ingelheim Pharma Drug compositions useful for treatment of respiratory diseases, especially asthma and chronic obstructive pulmonary disease comprises tiotropium salts and salmeterol salts

Also Published As

Publication number Publication date
PL375868A1 (en) 2005-12-12
ZA200503546B (en) 2006-10-25
CA2510043A1 (en) 2004-07-01
MXPA05006383A (en) 2005-08-29
EP1575588A1 (en) 2005-09-21
IL169178A0 (en) 2007-07-04
AU2003303029A1 (en) 2004-07-09
WO2004054580A1 (en) 2004-07-01
KR20050085650A (en) 2005-08-29
JP2006510680A (en) 2006-03-30
CN1726038A (en) 2006-01-25
RU2005122444A (en) 2007-01-27

Similar Documents

Publication Publication Date Title
BR0317340A (en) Hfc formulations in tiotropium containing solution
ATE409461T1 (en) HFC SOLUTION FORMULATIONS CONTAINING AN ANTICHOLINERGIC
CY1112523T1 (en) LIQUID COMPOSITIONS OF CANNIVOIDES FOR Mucosal Administration
KR950703932A (en) Stabilized medicinal aerosol solution formulations
BRPI0412059A (en) Method for preparing controlled release formulation
BR0306214A (en) 4-Oxoquinoline Compound and Use of It as an HIV Integrase Inhibitor
BR0013648A (en) Benzamide derivative-containing pharmaceutical formulation having improved oral solubility and absorption
ES2088312T3 (en) CONTROLLED RELEASE FORMULATION CONTAINING TRAMADOL.
BRPI0406905A (en) Clindamycin Phosphate Foam
UY28510A1 (en) CHEMICAL COMPOUNDS
ES2106360T3 (en) PHARMACEUTICAL FORMULATIONS OF AEROSOL CONTAINING BECLOMETASONE DIPROPIONATE.
AR055363A1 (en) PHARMACEUTICAL FORMULATIONS THAT INCLUDE A BETA 2- LONG-TERM AGONIST FOR ADMINISTRATION BY NEBULIZATION
PE20040321A1 (en) TOPICAL COMPOSITION INCLUDING DICLOFENACO
HN2008001666A (en) ACID DERIVATIVES OF CICLOALQUILAMINO
AR044200A1 (en) COMPOSITION OF FONDAPARINUX SODICO DE HIGH PURITY, A PROCEDURE FOR THE PREPARATION OF THIS COMPOSITION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT AS AN ACTIVE PRINCIPLE
PE20070353A1 (en) HFC SOLUTION FORMULATIONS CONTAINING SALBUTAMOL HYDROCHLORIDE OR SALBUTAMOL CITRATE
PA8532001A1 (en) USEFUL BIFENYL CARBOXAMIDS AS LIPID REDUCING AGENTS
BR0311363A (en) Immediate release pharmaceutical formulation, use thereof, and method for treating a cardiovascular disorder in a patient
CL2004001325A1 (en) A PHARMACEUTICAL COMPOSITION OF AEROSOL THAT INCLUDES CUBESONIDE SOLUBILIZED IN A PROPELLENT HYDROFLUOROCARBON AND A CO-SOLVENT, OF ETHANOL PREFERENCE, USEFUL AS ANTI-INFLAMMATORY OF THE AIRWAYS.
BR0013283A (en) Pharmaceutical agent comprising a benzamide derivative as active ingredient
ECSP045358A (en) AEROSOL FORMULATION FOR INHALATION CONTAINING A TIOTRIPE SALT
PE20030092A1 (en) FORMULATION OF AN INHALATION SOLUTION WITH A TIOTROPE SALT
WO2004069187A3 (en) Drug formulation and delivery using crystalline methylated cyclodextrins
ES2123808T3 (en) DERIVATIVE OF ACILFENILGLICINA AND PROPHYLCITIC AND CURATIVE AGENT FOR DISEASES CAUSED BY AN INCREASED ACTIVITY OF COLAGENASE, WHICH CONTAINS SUCH COMPOUND AS AN ACTIVE INGREDIENT.
PT97164A (en) METHOD FOR STABILIZING A PREPARATION CONTAINING THE COMPOUND 4-ETHYL-2-HYDROXY-IMINO-5-NITRO-3-HEXENAMIDE AND OF PHARMACEUTICAL COMPOSITIONS CONTAINING IT

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A, 6A E 7A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2073 DE 28/09/2010.